ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Acute myeloïde leukemie (AML) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Acute myeloïde leukemie' van de HOVON Leukemie werkgroep.

Klik HIER voor het consensus document MRD bij AML (2018) van de ELN MRD werkgroep.

Klik HIER voor het consensus document MRD bij AML (2021) van de ELN MRD werkgroep.

Literatuur

  1. Arber D.A. et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical and genomic data. Blood 2022 - 140 (11): 1200-1228
  2. Pratz et al. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALA-A. Am J Hematol. 2022 Nov; 97(11):E416-E419
  3. Döhner et al. Diagnosis and management of AML in adults: 2022 recommen­dations from an international expert panel on behalf of the ELN. Blood 2022; 140(12): 1345-1377 
  4. Schuurhuis GJ et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2018; 131(12): 1275-1291. doi: 10.1182/blood-2017-09-801498
  5. Heuser M. et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138(26): 2753-2767. doi: 10.1182/blood.2021013626
  6. Terwijn M et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013; 31(31): 3889-3897. e-pub ahead of print 2013/09/26; doi: 10.1200/JCO.2012.45.9628
  7. Zeijlemaker W et al. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia 2016; 30(3): 708-715. e-pub ahead of print 2015/09/17; doi: 10.1038/leu.2015.255
  8. Ivey A et al. Assessment of Minimal Residual Disease in Standard-Risk AML. The New England journal of medicine 2016. doi: 10.1056/NEJMoa1507471
  9. Ehinger M, Pettersson L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS 2019. e-pub ahead of print 2019/03/29; doi: 10.1111/apm.12926
  10. Wang Y et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood 2014; 124(12): 1880-1886. e-pub ahead of print 2014/08/02; doi: 10.1182/blood-2014-03-563403
  11. Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 129:424-447
  12. Arber D.A. et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 127:2391-2405
  13. Sorror M.L. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 106: 2912-2919
  14. Tettero J.M. et al. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry B Clin Cytom. 2023 Nov; 104(6):426-439. doi 10.1002/cyto.b.22144. Epub 2023 Sep 28
  15. Versluis J. et al. Risk stratification in older intensively treated patients with AML. J Clin Oncol. 42:4084-4094
  16. Lachowiez C.A. et al. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML. Blood (2024) 144 (26):2788-2792

 

Ga terug naar de AML homepage of lees meer over AML:

Ga terug naar de algemene homepage Behandelprotocollen.